Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CAPLACIZUMAB Cause Platelet count decreased? 12 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Platelet count decreased have been filed in association with CAPLACIZUMAB (Cablivi). This represents 8.3% of all adverse event reports for CAPLACIZUMAB.

12
Reports of Platelet count decreased with CAPLACIZUMAB
8.3%
of all CAPLACIZUMAB reports
2
Deaths
5
Hospitalizations

How Dangerous Is Platelet count decreased From CAPLACIZUMAB?

Of the 12 reports, 2 (16.7%) resulted in death, 5 (41.7%) required hospitalization, and 1 (8.3%) were considered life-threatening.

Is Platelet count decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CAPLACIZUMAB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does CAPLACIZUMAB Cause?

Off label use (26) Condition aggravated (13) Drug ineffective (10) Maternal exposure during pregnancy (10) Pyrexia (10) Thrombotic thrombocytopenic purpura (10) Foetal exposure during pregnancy (9) Foetal growth restriction (9) Haemorrhage (9) Deep vein thrombosis (8)

What Other Drugs Cause Platelet count decreased?

LENALIDOMIDE (7,491) NIRAPARIB (4,102) ELTROMBOPAG OLAMINE (3,419) RUXOLITINIB (3,028) RITUXIMAB (2,404) VENETOCLAX (2,367) DEXAMETHASONE (2,321) PALBOCICLIB (2,277) CYCLOPHOSPHAMIDE (1,894) RIBAVIRIN (1,701)

Which CAPLACIZUMAB Alternatives Have Lower Platelet count decreased Risk?

CAPLACIZUMAB vs CAPLACIZUMAB-YHDP CAPLACIZUMAB vs CAPMATINIB CAPLACIZUMAB vs CAPREOMYCIN CAPLACIZUMAB vs CAPSAICIN CAPLACIZUMAB vs CAPTOPRIL

Related Pages

CAPLACIZUMAB Full Profile All Platelet count decreased Reports All Drugs Causing Platelet count decreased CAPLACIZUMAB Demographics